{"nct_id":"NCT05984199","title":"Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant","status":"TERMINATED","status_verified_date":"2025-05","start_date":"2023-12-11","start_date_type":"ACTUAL","primary_completion_date":"2025-05-28","primary_completion_date_type":"ACTUAL","completion_date":"2025-05-28","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["VOR"]}